Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2012
02/09/2012WO2012019049A1 Devices, systems, and methods for excavating cancer cells
02/09/2012WO2012019047A2 Subconjunctival implant for posterior segment drug delivery
02/09/2012WO2012019029A2 Treatment of mitochondrial diseases with naphthoquinones
02/09/2012WO2012019021A1 Methods and pharmaceutical compositions for treating adverse or deleterious sequellae of traumatic brain injury
02/09/2012WO2012019015A2 Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
02/09/2012WO2012019003A1 Substituted indole and azaindole oxoacetyl piperazinamide derivatives
02/09/2012WO2012018980A2 Compositions and methods for treating inflammatory diseases
02/09/2012WO2012018950A1 Methods and compositions for treatment of metabolic disorders
02/09/2012WO2012018949A2 Compositions and methods for the treatment of cancer
02/09/2012WO2012018948A2 Novel treatment of prostate carcinoma
02/09/2012WO2012018932A2 Compounds and compositions for mitigating tissue damage and lethality
02/09/2012WO2012018909A1 Fused heterocyclic compounds
02/09/2012WO2012018868A1 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat proteins
02/09/2012WO2012018854A2 Pactamycin analogs and methods of use
02/09/2012WO2012018810A1 St-246 liquid formulations and methods
02/09/2012WO2012018795A1 Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals
02/09/2012WO2012018791A2 Preparation of prasugrel hydrochloride
02/09/2012WO2012018773A1 Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
02/09/2012WO2012018761A2 Method of treatment of androgen-mediated cancers
02/09/2012WO2012018759A2 Method of treatment of androgen-mediated cancers
02/09/2012WO2012018742A2 Dextromethorphan antitussive compositions
02/09/2012WO2012018704A1 Use of teriflunomide for treating multiple sclerosis
02/09/2012WO2012018665A1 Fused-imidazoyl compounds useful as antimicrobial agents
02/09/2012WO2012018643A2 Compositions for proliferation of cells and related methods
02/09/2012WO2012018635A2 Arylsulfonamide derivatives, compositions, and methods of use
02/09/2012WO2012018597A2 Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments
02/09/2012WO2012018594A2 Plant-derived polysaccharides for delivery of rna-based therapies
02/09/2012WO2012018540A1 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof
02/09/2012WO2012018534A2 Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
02/09/2012WO2012018499A2 Specific regulation of cytokine levels by hdac6 inhibitors
02/09/2012WO2012018383A2 Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof
02/09/2012WO2012018377A2 Liposome targeting compounds and related uses
02/09/2012WO2012018325A1 Hepatitis c virus inhibitors
02/09/2012WO2012018257A1 Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
02/09/2012WO2012018235A2 Method for preparing decitabine with improved yield and purity
02/09/2012WO2012018145A2 Agent for improving quality of life
02/09/2012WO2012018115A1 Composition for regeneratng normal tissue from fibrotic tissue
02/09/2012WO2012018105A1 Crystal of anti-bacterial compound
02/09/2012WO2012018069A1 Preparation for treatment of spinal cord injury
02/09/2012WO2012018065A1 Process for preparing compound having hiv integrase inhibitory activity
02/09/2012WO2012018059A1 Heterocyclic compound
02/09/2012WO2012018058A1 Fused heterocyclic ring compound
02/09/2012WO2012018056A1 Compressed composition
02/09/2012WO2012017932A1 Process for preparing compound by novel sandmeyer-like reaction using nitroxide radical compound as reaction catalyst
02/09/2012WO2012017892A1 Transdermal patch and method for augmenting adhesive strength thereof
02/09/2012WO2012017876A1 P2x4 receptor antagonist
02/09/2012WO2012017615A1 Aqueous gel composition of drug volatilization body
02/09/2012WO2012017555A1 Elastase inhibitor
02/09/2012WO2012017551A1 Therapeutic agent for disease
02/09/2012WO2012017454A1 Coumarin-chalcones as anticancer agents
02/09/2012WO2012017451A1 A bio-stabilized resveratrol formulation
02/09/2012WO2012017449A1 Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
02/09/2012WO2012017430A2 Microrna patterns for the diagnosis, prognosis and treatment of melanoma
02/09/2012WO2012017406A1 Exogenous pulmonary surfactant preparation comprising a phospholipid and an adjuvans
02/09/2012WO2012017405A1 Microparticle formulation for pulmonary drug delivery of anti-infective molecule for treatment of infectious diseases
02/09/2012WO2012017385A2 Beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and process for obtaining them
02/09/2012WO2012017383A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating biopolymer, beclomethasone dipropionate, terbinafine hydrochloride and a process to make it
02/09/2012WO2012017382A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating biopolymer, beclomethasone dipropionate, miconazole nitrate and a process make it
02/09/2012WO2012017381A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating, biopolymer, beclomethasone dipropionate, clotrimazole and a process to make it
02/09/2012WO2012017372A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating, biopolymer, clobetasol propionate, miconazole nitrate and a process to make it
02/09/2012WO2012017371A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, clobetasole propionate, terbinafine hydrochloride and a process to make it
02/09/2012WO2012017370A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, betamethasone dipropionate, terbinafine hydrochloride and a process to make it
02/09/2012WO2012017369A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating biopolymer, betamethasone dipropionate, clotrimazole and a process to make it
02/09/2012WO2012017368A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
02/09/2012WO2012017367A1 Composition comprising glutathione reductase and oxidized glutathione, and therapeutic uses thereof
02/09/2012WO2012017349A2 An improved topical pharmaceutical composition comprising nanonized silver sulfadiazine
02/09/2012WO2012017321A2 Treatment for dyslipidemia
02/09/2012WO2012017290A1 Inclusion complexes of cyclodextrins with spermidine, and proliferative/reparative compositions comprising thereof
02/09/2012WO2012017288A2 Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair
02/09/2012WO2012017251A1 N-acylsulfonamide apoptosis promoters
02/09/2012WO2012017239A2 Chemical compounds
02/09/2012WO2012017216A1 Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent
02/09/2012WO2012017215A1 Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine
02/09/2012WO2012017204A1 Efficient and cost-effective process for the manufacture of amyl m-cresol
02/09/2012WO2012017186A1 Compositions comprising oleuropeins and flavanoids and their use
02/09/2012WO2012017166A2 Benzenesulfonamide-compound treatment of a pathological condition linked to an excessive effect of tnf
02/09/2012WO2012017128A2 Composition based on rosemary extract and vitamin e and uses thereof
02/09/2012WO2012017088A1 Use of inhibitors of porphobilinogen deaminase in the treatment of congenital erythropoietic porphyria
02/09/2012WO2012017077A1 Combination of compounds for treating or preventing skin diseases
02/09/2012WO2012017074A1 Oral pharmaceutical formulations of esomeprazole in the form of mups (multi unit pellets system) tablets
02/09/2012WO2012017030A1 Compounds with antibacterial activity against clostridium
02/09/2012WO2012017029A1 Novel salts of saxagrliptin with organic di-acids
02/09/2012WO2012017028A1 A novel crystalline compound comprising saxagliptin and phosphoric acid
02/09/2012WO2012017027A1 Acid addition salts of the 2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-(methyl)amino]ethoxy]-n-methyl-n-[3-(4-methylpiperazin-1-yl)cyclohexyl] acetamide and the use thereof as bradykinin b1 receptor antagonists
02/09/2012WO2012017020A1 N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein
02/09/2012WO2012017004A1 Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties
02/09/2012WO2012016995A1 Prediction of hcv viral kinetics in interferon-free treatment
02/09/2012WO2012016994A1 Bone-targeting bisphosphonate duplex drugs
02/09/2012WO2012016993A1 Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
02/09/2012WO2012016980A2 Use of sigma ligands in opioid-induced hyperalgesia
02/09/2012WO2012016978A1 Glycolipid for treatment of ischemia reperfusion injury
02/09/2012WO2012016970A1 A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor
02/09/2012WO2012016969A1 Highly crystalline valsartan
02/09/2012WO2012016930A1 Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
02/09/2012WO2012016889A2 Dry powder formulation comprising a phosphodiesterase inhibitor
02/09/2012WO2012016879A1 Combinations comprising atypical antipsychotics and taar1 agonists
02/09/2012WO2012016876A1 Therapeutic combination comprising a parp-1 inhibitor and an anti-neoplastic agent
02/09/2012WO2012016845A2 Pharmaceutical formulation comprising a phosphodiesterase inhibitor
02/09/2012WO2012016708A1 Oral dosage form comprising dimebolin and donepezil
02/09/2012WO2012016707A2 Oral dosage form for the modified release of dimebolin
1 ... 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 ... 7860